Citi raised the firm’s price target on Sight Sciences (SGHT) to $3.60 from $3.20 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences, Inc. Earnings Call: Mixed Results and Strategic Focus
- Sight Sciences price target raised to $3 from $2.50 at Lake Street
- Sight Sciences: Balancing Resilience and Caution Amid Tariff Challenges
- Sight Sciences Reports Q1 2025 Earnings and Outlook
- Sight Sciences Reports Q1 2025 Financial Results